Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
88 hedge funds and large institutions have $1.01B invested in Odonate Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 35 increasing their positions, 24 reducing their positions, and 7 closing their positions.
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
46% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 24
24% more capital invested
Capital invested by funds: $818M → $1.01B (+$196M)
7% more funds holding
Funds holding: 82 → 88 (+6)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$4.3M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$2.32M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.08M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$781K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.41M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$1.84M |
| 4 |
Millennium Management
New York
|
-$1.44M |
| 5 |
Two Sigma Investments
New York
|
-$1.24M |
ODT Hedge Fund Activity: Q4 2019 in Review
88 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q4 2019, worth a combined $1.01B — up 24% from $818M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ODT positions and 7 closed out — a net gain of 6 holders — while 35 added to existing stakes and 24 trimmed.
The largest buyer was Driehaus Capital Management, adding an estimated $4.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $5.21M sold.
- 88 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q4 2019, up from 82 in Q3 2019.
- Funds reported $1.01B of Odonate Therapeutics, Inc. Common Stock stock for Q4 2019, up 24% quarter-over-quarter.
- 13 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q4 2019 and 7 closed out, a net change of +6 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q4 2019 was Driehaus Capital Management, an estimated $4.3M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q4 2019 was RA Capital Management, an estimated $5.21M sold.
Based on aggregated 13F filings for Q4 2019.